

CanAssistBreast®

Next Generation Sequencing based test to
detect genomic biomarker

What is CanAssistBreast®?

CanAssistBreast® combines

Expression analysis of 5 protein biomarkers	Tumor size
Tumor grade	Lymph node status

Using a **proprietary AL-ML
algorithm**, patients are classified into

High Risk

- ~30% of patients
- Higher likelihood of cancer recurrence
- May benefit from chemotherapy or additional treatment options

Low Risk

- ~70% of patients
- Lower likelihood of cancer recurrence
- May help avoid unnecessary chemotherapy & its side effects

Who is Eligible for CanAssistBreast®?

Eligible	Not Eligible
Stage I-II invasive breast cancer	Pure DCIS
ER+/PR+	Hormone receptor-negative
HER2-negative	>3 positive lymph nodes
0-3 positive lymph nodes	Tumor size >5 cm
Any tumor grade	Received neoadjuvant therapy
-	HER2-positive
-	Triple-negative breast cancer (TNBC)

Key Advantages of CanAssistBreast®

Developed for Asian patients

Clinically validated internationally

Supports personalized treatment decisions

Cost-effective compared with many genomic tests

Fast turnaround time - results within 8 working days

How Does the Test Work?

1

Tumor tissue collected during surgery

2

FFPE sample sent for testing

3

CAP Accredited Lab analyzes biomarker & clinical parameters

4

A recurrence risk report is generated

5


Results available within 8 working days

CAB Dummy Report

TEST RESULT



5 YEAR PROBABILITY OF DISTANT RECURRENCE



5 Year Probability of Distant Recurrence
with Hormone Therapy and Prescribed
Local Radiotherapy

4 %


Probability of distant recurrence derived from
800+ samples validation study ² is represented
in the graph.

Figure 1 shows the result for low risk of recurrence

TEST RESULT



5 YEAR PROBABILITY OF DISTANT RECURRENCE



5 Year Probability of Distant Recurrence
with Hormone Therapy and Prescribed
Local Radiotherapy

20 %

Probability of distant recurrence derived from
800+ samples validation study ² is represented
in the graph.

Figure 2 shows the result for high risk of recurrence

OncoStem

OncoStem Diagnostics is a precision oncology company dedicated to improving cancer care through innovative prognostic testing. by integrating biomarker research with advanced analytical technologies, the company provides clinically actionable insights that support personalized treatment decisions. its solutions help clinicians assess recurrence risk and optimize patient management.

Witty Charman Medical

Witty Charman delivers medical technology, clinical services, wellness and enables Next Generation Genetic Testing services. It's in Tenth year of service to Malaysia . It was founded with a vision to improve healthcare through affordable, innovative & compassionate solutions for Paediatrics to Geriatrics.

Contact info



Wendy Khoo



Samantha Lee



+60 12-387 8395



+60 12-694 0055



wendy@wittycharman.com



samantha@wittycharman.com



UG-D12, Utropolis Marketplace, Jalan
Kontraktor U1/14, Seksyen U1
Glenmarie, 40150 Shah Alam, Selangor,
Malaysia.

